Latest Auxilium Pharmaceuticals Inc. Stories
- Auxilium to exercise the exclusive option to expand the field of its license of CCH to include the potential treatment of canine lipoma LYNBROOK, N.Y., Nov.
Multiple Presentations Designed to Enable a Better Understanding of the Safety and Efficacy Profile of XIAFLEX for Treatment of Peyronie's Disease CHESTERBROOK, Pa., Nov.
$109.6 Million in 3Q 2014 Net Revenues Driven by Strong XIAFLEX Growth; Company Returns to Profitability with 3Q Non-GAAP EPS of $0.27 per Share CHESTERBROOK, Pa., Oct.
- Label expansion to broaden patient base who may benefit from nonsurgical collagenase therapy LYNBROOK, N.Y., Oct.
Estimated 35-40 Percent of Surgical Procedures to Treat DC Have Been Performed on Multiple Joints CHESTERBROOK, Pa., Oct.
NEW ORLEANS, Oct. 13, 2014 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
- Auxilium Shareholders to Receive $33.25 Per Share DUBLIN and CHESTERBROOK, Pa., Oct.
Board Unanimously Reaffirms Recommendation of QLT Transaction CHESTERBROOK, Pa., Sept. 22, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc.
Data Support CCH could be Used to Treat Two Affected Joints Concurrently; Positive Results Presented from Additional Studies Evaluating CCH Retreatment for Recurrent Contracture CHESTERBROOK,
- A serpent whose bite was fabled to produce intense thirst.